Oncothyreon Inc. · Seattle, WA United States (NASDAQ: ONTY)
| 2601 4th Ave., Ste. 500 | Phone: 206-801-2100 |
| Seattle, WA | Fax: 206-801-2101 |
| 98121 | |
| United States | 
Map This Company |
Oncothyreon Inc. Rankings
Company Description
Beating cancer is Oncothyreon's sole goal. The biotechnology company is developing synthetic vaccines and small-molecule (chemical) drugs that aim to battle the dread disease. Oncothyreon's vaccine candidates stimulate cancer-fighting elements in patients' immune systems. Lead candidate Stimuvax is a potential vaccine for non-small cell lung cancer that the company has licensed to Germany's
Oncothyreon Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ONTY Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 25 |
Executives
14 executives listed for Oncothyreon Inc.'s Seattle, WA location.
| Chairman | Christopher Henney | |
|---|---|---|
| President, CEO, and Director | Robert Kirkman | |
| COO | Gary Christianson |